ZYNERBA PHARMACEUTICALS INC (ZYNE)
US98986X1090 - Common Stock
ZYNERBA PHARMACEUTICALS INC
NASDAQ:ZYNE (10/10/2023, 7:00:03 PM)
After market: 1.3015 +0 (+0.12%)1.3
+0.03 (+2.36%)
Company Profile
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2015-08-05. The firm is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). The company is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). The company uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
Company Info
ZYNERBA PHARMACEUTICALS INC
80 W. Lancaster Avenue, Suite 300
Devon PENNSYLVANIA 19333
P: 14845817505.0
CEO: Armando Anido
Employees: 25
Website: https://www.zynerba.com/
ZYNE News
7 months ago - The Motley FoolWhy Shares of Harmony Bioscience Are Falling on FridayThe company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.
7 months ago - Zynerba Pharmaceuticals, Inc.Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsDEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced...
7 months ago - Zynerba Pharmaceuticals, Inc.Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced...
8 months ago - Zynerba Pharmaceuticals, Inc.Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumZygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)
ZYNE Twits
Here you can normally see the latest stock twits on ZYNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
